The COVID-19 pandemic has brought unprecedented challenges to the world. CD BioGlyco has combined multiple technology platforms to provide customers with comprehensive and accurate viral glycomics information to speed up the development of vaccines and other therapeutic agents. We have confidence to be your essential research assistant in the field of glycobiology.
Coronavirus disease 2019 (COVID-19) pandemic, caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has dramatically impacted human health and the global economy. From the discovery of the virus in early January 2020 to November 2020, the virus has infected more than 60 million people worldwide and caused more than 1.4 million deaths. Understanding virus attachment patterns, entry, and replication has become a critical step in interventions has become a key step in interventions.
The scientific community is still making great efforts to understand the virus in many aspects and compile useful data. The virus uses the spike protein (S protein) to bind angiotensin-converting enzyme 2 (ACE-2) to cause infection. S protein is a highly glycosylated protein, containing 22 N-linked and 3 O-linked glycosylation sites, which is a key protein that affects virus infection and vaccine preparation. Therefore, it has become the focus of attention in academia and industry.
To better understand the variation of S protein and its potential impact on the host immune system, researchers are performing glycosylation profiling, characterizing its changes during the global spread and comparing it with the glycosylation characteristics of SARS-COV.
Fig 1. MD simulation of glycosylated soluble human ACE2 and glycosylated SARS-CoV-2 S trimer immunogen interaction. ACE2 (top) is colored red with glycans in pink, whereas S is colored white with glycans in dark gray. (Zhao, P. et al. 2020)
CD BioGlyco integrates our most advanced technology platforms and do our best to promote coronavirus research. We provide the following services to help scientists around the world to better study SARS-CoV-2.
CD BioGlyco is committed to developing various technology platforms to help scientists around the world explore the coronavirus and promote the global vaccine development process. CD BioGlyco has professional teams and ultra-high-precision instruments. We are confident that we can provide customers with high-quality viral glycomics research.
Clients can reach our scientists directly via email or phone to receive prompt response. If you are interested in our services, please contact us for more detailed information.